Chemotherapy-Induced Nausea and Vomiting: Developing Drugs for Prevention

On 19 May 2021 the FDA published this draft guidance for industry. Comments should be submitted by 19 July 2021.

The purpose of this guidance is to help sponsors in the clinical development of drugs for the prevention of chemotherapy-induced nausea and vomiting (CINV) in adults. Specifically, this guidance addresses FDA’s current recommendations on clinical trials for drugs being developed under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355) and 21 CFR Parts 312 and 314 for the prevention of CINV and considerations for eligibility criteria, trial design features, efficacy evaluations, and clinical outcome assessments.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /